Literature DB >> 25455720

Severe infections in patients with autoimmune diseases treated with cyclophosphamide.

Javier A Cavallasca1, Cecilia A Costa2, Maria Del Rosario Maliandi2, Liliana E Contini2, Elena Fernandez de Carrera2, Jorge L Musuruana2.   

Abstract

INTRODUCTION: Infectious diseases are a significant cause of morbidity and mortality in patients with connective tissue diseases. Corticosteroids and immunosuppressive drugs, such as cyclophosphamide (CYC), increases the risk of infections. The objective of this study was to estimate the incidence rates of severe infections in patients who received treatment with CYC. PATIENTS AND METHODS: The records of 60 patients with systemic autoimmune diseases who received treatment with CYC were retrospectively reviewed. We evaluated the rate of severe infections that occurred during CYC therapy and the 3 subsequent months.
RESULTS: Systemic lupus erythematosus was the most common disease, and diffuse proliferative glomerulonephritis the most frequent indication. Severe infection occurred in 9 patients (15%). Community acquired pneumonia was the most frequent infection with 3 cases (33%) followed by Herpes Zoster with 2 reports (22%). The cumulative dose of corticosteroid was the only significant risk factor for infection 32.8±16.7 vs. 20.1±15.3 P=.007.
CONCLUSION: The use of lower doses of corticosteroids and an aggressive management of infectious complications, allows for an acceptable safety profile in patients treated with CYC.
Copyright © 2014 Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Ciclofosfamida; Connective tissue diseases; Corticoides; Corticosteroids; Cyclophosphamide; Enfermedades autoinmunes sistémicas; Infecciones; Infections, Immunosuppressive drugs; Inmunosupresores

Mesh:

Substances:

Year:  2014        PMID: 25455720     DOI: 10.1016/j.reuma.2014.09.003

Source DB:  PubMed          Journal:  Reumatol Clin        ISSN: 1699-258X


  7 in total

Review 1.  Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases.

Authors:  Luis Malpica; Stephan Moll
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

2.  Phosphodiesterase1 inhibitor "Vinpocetine" ameliorates the inflammation, apoptosis and oxidative stress induced by cyclophosphamide in urinary bladder: an experimental study.

Authors:  Rehab Sabri Abdelrahman; Eman Mohamad El Nashar; Mansour Abdullah Alghamdi; Khulood Mohammed Al-Khater; Reham Ismail Taha
Journal:  Int Urol Nephrol       Date:  2022-07-11       Impact factor: 2.266

Review 3.  Revisited Cyclophosphamide in the Treatment of Lupus Nephritis.

Authors:  Xiao-Ying Quan; Hao-Tao Chen; Si-Qin Liang; Chen Yang; Cui-Wei Yao; Yong-Zhi Xu; Hua-Feng Liu; Ning An
Journal:  Biomed Res Int       Date:  2022-05-26       Impact factor: 3.246

Review 4.  Developments in Varicella Zoster Virus Vasculopathy.

Authors:  Maria A Nagel; Don Gilden
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 6.030

5.  Mesenchymal Stem Cells Enhance Pulmonary Antimicrobial Immunity and Prevent Following Bacterial Infection.

Authors:  Wenchao Li; Weiwei Chen; Saisai Huang; Xiaojun Tang; Genhong Yao; Lingyun Sun
Journal:  Stem Cells Int       Date:  2020-03-28       Impact factor: 5.443

Review 6.  Current status of xenotransplantation research and the strategies for preventing xenograft rejection.

Authors:  Qiao Zhou; Ting Li; Kaiwen Wang; Qi Zhang; Zhuowen Geng; Shaoping Deng; Chunming Cheng; Yi Wang
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

7.  Infectious Complications in Patients with Primary Glomerulonephritis over 10 Years: A Single-Center Experience in Turkey.

Authors:  Rezzan Eren Sadioglu; Sahin Eyupoglu; Siyar Erdogmus; Gizem Kumru Sahin; Fugen Yoruk; Sim Kutlay; Kenan Keven; Sehsuvar Erturk; Sule Sengul
Journal:  Kidney Dis (Basel)       Date:  2020-09-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.